VX-680 (MK-0457, Tozasertib)
Catalog No. A10981
VX-680 (MK-0457,Tozasertib)是一种有效的选择性Aurora激酶小分子抑制剂。
- Sakamoto K, .et al. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response, Leukemia, 2018, May 23 PMID: 29795241
- W. Joost Lesterhuis, .et al. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations, Sci Rep, 2015, 5: 12298 PMID: 26193793
Catalog Num | A10981 |
---|---|
M. Wt | 464.6 |
Formula | C23H28N8OS |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 639089-54-6 |
Synonyms | |
SMILES | CC1=CC(=NN1)NC2=NC(=NC(=C2)N3CCN(CC3)C)SC4=CC=C(C=C4)NC(=O)C5CC5 |
VX-680 (MK-0457,Tozasertib)是一种有效的选择性Aurora激酶小分子抑制剂。
Targets
Aurora A (Cell-free assay) | Aurora C (Cell-free assay) | Aurora B (Cell-free assay) | FLT3 (Cell-free assay) | Bcr-Abl (Cell-free assay) |
0.6 nM(Ki app) | 4.6 nM(Ki app) | 18 nM(Ki app) | 30 nM(Ki) | 30 nM(Ki) |
In vitro (25°C) | DMSO | 90 mg/mL (193.71 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 5% DMSO+30% PEG 300+2% Tween 80+ddH2O | 14 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 21.52 mL | 107.62 mL | 215.24 mL |
0.5 mM | 4.3 mL | 21.52 mL | 43.05 mL |
1 mM | 2.15 mL | 10.76 mL | 21.52 mL |
5 mM | 0.43 mL | 2.15 mL | 4.3 mL |
*The above data is based on the productmolecular weight 464.6 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.